Cargando…
P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171704/ http://dx.doi.org/10.1097/01.HS9.0000936252.25785.17 |
| _version_ | 1785039479858266112 |
|---|---|
| author | Nooka, A. Cohen, A. Lee, H. Badros, A. Suvannasankha, A. Callander, N. Abdallah, A. Trudel, S. Chari, A. Libby, E. Chaudhry, M. Hultcrantz, M. Kortüm, K.M. Richardson, P. Popat, R. Sborov, D. Hakim, S. Lewis, E. Bhushan, B. Gorsh, B. Gupta, I. Opalinska, J. Lonial, S. |
| author_facet | Nooka, A. Cohen, A. Lee, H. Badros, A. Suvannasankha, A. Callander, N. Abdallah, A. Trudel, S. Chari, A. Libby, E. Chaudhry, M. Hultcrantz, M. Kortüm, K.M. Richardson, P. Popat, R. Sborov, D. Hakim, S. Lewis, E. Bhushan, B. Gorsh, B. Gupta, I. Opalinska, J. Lonial, S. |
| author_sort | Nooka, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171704 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101717042023-05-11 P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL Nooka, A. Cohen, A. Lee, H. Badros, A. Suvannasankha, A. Callander, N. Abdallah, A. Trudel, S. Chari, A. Libby, E. Chaudhry, M. Hultcrantz, M. Kortüm, K.M. Richardson, P. Popat, R. Sborov, D. Hakim, S. Lewis, E. Bhushan, B. Gorsh, B. Gupta, I. Opalinska, J. Lonial, S. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171704/ http://dx.doi.org/10.1097/01.HS9.0000936252.25785.17 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Nooka, A. Cohen, A. Lee, H. Badros, A. Suvannasankha, A. Callander, N. Abdallah, A. Trudel, S. Chari, A. Libby, E. Chaudhry, M. Hultcrantz, M. Kortüm, K.M. Richardson, P. Popat, R. Sborov, D. Hakim, S. Lewis, E. Bhushan, B. Gorsh, B. Gupta, I. Opalinska, J. Lonial, S. P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL |
| title | P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL |
| title_full | P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL |
| title_fullStr | P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL |
| title_full_unstemmed | P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL |
| title_short | P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL |
| title_sort | p31 single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: final analysis of the dreamm-2 trial |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171704/ http://dx.doi.org/10.1097/01.HS9.0000936252.25785.17 |
| work_keys_str_mv | AT nookaa p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT cohena p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT leeh p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT badrosa p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT suvannasankhaa p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT callandern p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT abdallaha p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT trudels p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT charia p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT libbye p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT chaudhrym p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT hultcrantzm p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT kortumkm p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT richardsonp p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT popatr p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT sborovd p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT hakims p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT lewise p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT bhushanb p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT gorshb p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT guptai p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT opalinskaj p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial AT lonials p31singleagentbelantamabmafodotininpatientswithrelapsedorrefractorymultiplemyelomafinalanalysisofthedreamm2trial |